Neurology 2001;57:2253-2258
© 2001 American Academy of Neurology
Articles
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions
B. Ripley, BS,
S. Overeem, MSc,
N. Fujiki, MD PhD;,
S. Nevsimalova, MD PhD;,
M. Uchino, MD PhD;,
J. Yesavage, MD,
D. Di Monte, MD,
K. Dohi, MD PhD;,
A. Melberg, MD PhD;,
G. J. Lammers, MD PhD;,
Y. Nishida, MD,
F. W.C. Roelandse,
M. Hungs, MD PhD;,
E. Mignot, MD PhD; and
S. Nishino, MD PhD
From the Stanford University Center for Narcolepsy (Drs. Fujiki, Hungs, Mignot, and Nishino, and B. Ripley), Palo Alto, CA; Department of Neurology and Clinical Neurophysiology (Dr. Lammers, S. Overeem, and F.W.C. Roelandse), Leiden University Medical Center, Leiden, the Netherlands; Department of Neurology (Dr. Nevsimalova), 1st Medical Faculty, Charles University, Prague, Czech Republic; Department of Neurology (Drs. Uchino and Nishida), Kumamoto University, School of Medicine, Kumamoto, Japan; Department of Veterans Affairs Medical Center (Dr. Yesavage), Palo Alto, and Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA; The Parkinson’s Institute (Dr. Monte), Sunnyvale, CA; Department of Neurosurgery and Anatomy (Dr. Dohi), Showa University, School of Medicine, Shinagawa, Japan; and Department of Neuroscience (Dr. Melberg), Neurology, University Hospital, Uppsala, Sweden.
Address correspondence and reprint requests to Dr. Seiji Nishino, Stanford University, Center for Narcolepsy, 701B Welch Road, Rm 142, Palo Alto, CA 94304; e-mail: nishino{at}stanford.edu
Objective: To examine the specificity of low CSF hypocretin-1 levels in narcolepsy and explore the potential role of hypocretins in other neurologic disorders.
Methods: A method to measure hypocretin-1 in 100 µL of crude CSF sample was established and validated. CSF hypocretin-1 was measured in 42 narcolepsy patients (ages 16–70 years), 48 healthy controls (ages 22–77 years,) and 235 patients with various other neurologic conditions (ages 0–85 years).
Results: As previously reported, CSF hypocretin-1 levels were undetectably low (<100 pg/mL) in 37 of 42 narcolepsy subjects. Hypocretin-1 levels were detectable in all controls (224–653 pg/mL) and all neurologic patients (117–720 pg/mL), with the exception of three patients with Guillain–Barré syndrome (GBS). Hypocretin-1 was within the control range in most neurologic patients tested, including patients with AD, PD, and MS. Low but detectable levels (100–194 pg/mL) were found in a subset of patients with acute lymphocytic leukemia, intracranial tumors, craniocerebral trauma, CNS infections, and GBS.
Conclusions: Undetectable CSF hypocretin-1 levels are highly specific to narcolepsy and rare cases of GBS. Measuring hypocretin-1 levels in the CSF of patients suspected of narcolepsy is a useful diagnostic procedure. Low hypocretin levels are also observed in a large range of neurologic conditions, most strikingly in subjects with head trauma. These alterations may reflect focal lesions in the hypothalamus, destruction of the blood brain barrier, or transient or chronic hypofunction of the hypothalamus. Future research in this area is needed to establish functional significance.
This article has been cited by other articles:
|
|
|
|
 
T. Kanbayashi, T. Shimohata, I. Nakashima, H. Yaguchi, I. Yabe, M. Nishizawa, T. Shimizu, and S. Nishino
Symptomatic Narcolepsy in Patients With Neuromyelitis Optica and Multiple Sclerosis: New Neurochemical and Immunological Implications
Arch Neurol,
December 1, 2009;
66(12):
1563 - 1566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Parish
Genetic and Immunologic Aspects of Sleep Disorders
ACCP Sleep Med Brd Rev,
January 1, 2009;
4(0):
271 - 286.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Knudsen, P. Jennum, K Korsholm, S. Sheikh, S Gammeltoft, and J. Frederiksen
Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis
Multiple Sclerosis,
July 1, 2008;
14(6):
734 - 738.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. R. Baumann, T. E. Scammell, and C. L. Bassetti
Parkinson's disease, sleepiness and hypocretin/orexin
Brain,
March 1, 2008;
131(3):
e91 - e91.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-S. Deng, A. Nakamura, W. Zhang, M. Yanagisawa, Y. Fukuda, and T. Kuwaki
Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice
J Appl Physiol,
November 1, 2007;
103(5):
1772 - 1779.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ganjavi and C. M. Shapiro
Hypocretin/Orexin: A Molecular Link Between Sleep, Energy Regulation, and Pleasure
J Neuropsychiatry Clin Neurosci,
November 1, 2007;
19(4):
413 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Baumann, E. Werth, R. Stocker, S. Ludwig, and C. L. Bassetti
Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study
Brain,
July 1, 2007;
130(7):
1873 - 1883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fronczek, S. Overeem, S. Y. Y. Lee, Ingrid. M. Hegeman, J. van Pelt, Sjoerd. G. van Duinen, G. J. Lammers, and D. F. Swaab
Hypocretin (orexin) loss in Parkinson's disease
Brain,
June 1, 2007;
130(6):
1577 - 1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Friedman, J. M. Zeitzer, L. Lin, D. Hoff, E. Mignot, E. R. Peskind, and J. A. Yesavage
In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1
Neurology,
March 6, 2007;
68(10):
793 - 794.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Stiasny-Kolster, S.-C. Clever, J. C. Moller, W. H. Oertel, and G. Mayer
Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder
Brain,
February 1, 2007;
130(2):
442 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nakamura, W. Zhang, M. Yanagisawa, Y. Fukuda, and T. Kuwaki
Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice
J Appl Physiol,
January 1, 2007;
102(1):
241 - 248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Rojas-Marcos, F. Graus, G. Sanz, A. Robledo, and C. Diaz-Espejo
Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: Case study
Neuro Oncology,
January 1, 2007;
9(1):
75 - 77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Young and M. H. Silber
Hypersomnias of central origin.
Chest,
September 1, 2006;
130(3):
913 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hayes Jr
Narcolepsy with Cataplexy in Early Childhood
Clinical Pediatrics,
May 1, 2006;
45(4):
361 - 363.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Dhawan, D. G. Healy, S. Pal, and K. R. Chaudhuri
Sleep-related problems of Parkinson's disease.
Age Ageing,
May 1, 2006;
35(3):
220 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Baumann, R. Stocker, H. -G. Imhof, O. Trentz, M. Hersberger, E. Mignot, and C. L. Bassetti
Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury
Neurology,
July 12, 2005;
65(1):
147 - 149.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Rejdak, A Petzold, L Lin, M Smith, N Kitchen, and E J Thompson
Decreased CSF hypocretin-1 (orexin-A) after acute haemorrhagic brain injury
J. Neurol. Neurosurg. Psychiatry,
April 1, 2005;
76(4):
597 - 598.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Petersen, J. Gil, M. L.C. Maat-Schieman, M. Bjorkqvist, H. Tanila, I. M. Araujo, R. Smith, N. Popovic, N. Wierup, P. Norlen, et al.
Orexin loss in Huntington's disease
Hum. Mol. Genet.,
January 1, 2005;
14(1):
39 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Arii, T. Kanbayashi, Y. Tanabe, Y. Sawaishi, S. Kimura, A. Watanabe, K. Mishima, Y. Hishikawa, T. Shimizu, and S. Nishino
CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders
Neurology,
December 28, 2004;
63(12):
2440 - 2442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Beuckmann, C. M. Sinton, S. C. Williams, J. A. Richardson, R. E. Hammer, T. Sakurai, and M. Yanagisawa
Expression of a Poly-Glutamine-Ataxin-3 Transgene in Orexin Neurons Induces Narcolepsy-Cataplexy in the Rat
J. Neurosci.,
May 5, 2004;
24(18):
4469 - 4477.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Siebold, B. E. Hansen, J. R. Wyer, K. Harlos, R. E. Esnouf, A. Svejgaard, J. I. Bell, J. L. Strominger, E. Y. Jones, and L. Fugger
Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy
PNAS,
February 17, 2004;
101(7):
1999 - 2004.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Overeem, J. Dalmau, L. Bataller, S. Nishino, E. Mignot, J. Verschuuren, and G. J. Lammers
Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis
Neurology,
January 13, 2004;
62(1):
138 - 140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y Dauvilliers, C. Baumann, B Carlander, M Bischof, T Blatter, M Lecendreux, F Maly, A Besset, J Touchon, M Billiard, et al.
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions
J. Neurol. Neurosurg. Psychiatry,
December 1, 2003;
74(12):
1667 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Stiasny-Kolster, E. Mignot, L. Ling, J.C. Moller, W. Cassel, and W.H. Oertel
CSF hypocretin-1 levels in restless legs syndrome
Neurology,
November 25, 2003;
61(10):
1426 - 1429.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nishino, T. Kanbayashi, N. Fujiki, M. Uchino, B. Ripley, M. Watanabe, G. J. Lammers, H. Ishiguro, S. Shoji, Y. Nishida, et al.
CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies
Neurology,
September 23, 2003;
61(6):
823 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Chaudhuri
Nocturnal symptom complex in PD and its management
Neurology,
September 23, 2003;
61(90063):
S17 - 23.
[Full Text]
|
|
|
|
|
|
|
O. J. Dempsey, P. McGeoch, R. N. de Silva, and N. J. Douglas
Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation
Neurology,
August 26, 2003;
61(4):
537 - 540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Drouot, S. Moutereau, J.P. Nguyen, J.P. Lefaucheur, A. Creange, P. Remy, F. Goldenberg, and M.P. d'Ortho
Low levels of ventricular CSF orexin/hypocretin in advanced PD
Neurology,
August 26, 2003;
61(4):
540 - 543.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Overeem, S. W. Kok, G. J. Lammers, A. A. Vein, M. Frolich, A. E. Meinders, F. Roelfsema, and H. Pijl
Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events
Am J Physiol Endocrinol Metab,
March 1, 2003;
284(3):
E641 - E647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mignot, G. J. Lammers, B. Ripley, M. Okun, S. Nevsimalova, S. Overeem, J. Vankova, J. Black, J. Harsh, C. Bassetti, et al.
The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias
Arch Neurol,
October 1, 2002;
59(10):
1553 - 1562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Allen, E. Mignot, B. Ripley, S. Nishino, and C. J. Earley
Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome
Neurology,
August 27, 2002;
59(4):
639 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kubota, T. Kanbayashi, Y. Tanabe, and Y. Kohno
A Case of Acute Disseminated Encephalomyelitis Presenting Hypersomnia With Decreased Hypocretin Level in Cerebrospinal Fluid
J Child Neurol,
July 1, 2002;
17(7):
537 - 539.
[Abstract]
[PDF]
|
|
|
|
